SM17, a new IL‐17RB‐targeting antibody, ameliorates disease progression in a mouse model of atopic dermatitis

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. Appendix S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.